Free Trial

Adverum Biotechnologies (ADVM) Competitors

Adverum Biotechnologies logo
$2.68 +0.14 (+5.51%)
As of 01:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ADVM vs. CRGX, CYBN, EDIT, EPRX, ENGN, TLSA, CTMX, OGI, GNFT, and FDMT

Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include CARGO Therapeutics (CRGX), Cybin (CYBN), Editas Medicine (EDIT), Eupraxia Pharmaceuticals (EPRX), enGene (ENGN), Tiziana Life Sciences (TLSA), CytomX Therapeutics (CTMX), Organigram Global (OGI), GENFIT (GNFT), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry.

Adverum Biotechnologies vs. Its Competitors

CARGO Therapeutics (NASDAQ:CRGX) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

CARGO Therapeutics currently has a consensus target price of $15.40, suggesting a potential upside of 235.88%. Adverum Biotechnologies has a consensus target price of $23.80, suggesting a potential upside of 788.06%. Given Adverum Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than CARGO Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CARGO Therapeutics
1 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.86
Adverum Biotechnologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, CARGO Therapeutics had 14 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 14 mentions for CARGO Therapeutics and 0 mentions for Adverum Biotechnologies. CARGO Therapeutics' average media sentiment score of 0.47 beat Adverum Biotechnologies' score of 0.00 indicating that CARGO Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
CARGO Therapeutics Neutral
Adverum Biotechnologies Neutral

Adverum Biotechnologies has higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CARGO TherapeuticsN/AN/A-$167.50M-$4.62-0.99
Adverum Biotechnologies$1M55.99-$130.93M-$6.40-0.42

CARGO Therapeutics' return on equity of -45.93% beat Adverum Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
CARGO TherapeuticsN/A -45.93% -39.58%
Adverum Biotechnologies N/A -130.53%-66.31%

CARGO Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 2.9% of CARGO Therapeutics shares are owned by insiders. Comparatively, 6.0% of Adverum Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Adverum Biotechnologies beats CARGO Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADVM vs. The Competition

MetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$55.88M$2.96B$5.58B$9.01B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-0.4221.4727.5120.20
Price / Sales55.99259.84415.84172.51
Price / CashN/A41.8337.0657.97
Price / Book0.797.788.085.61
Net Income-$130.93M-$55.05M$3.17B$248.50M
7 Day Performance12.37%5.38%3.57%4.92%
1 Month Performance-3.94%3.87%3.74%7.42%
1 Year Performance-65.55%5.72%33.78%21.48%

Adverum Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADVM
Adverum Biotechnologies
4.0802 of 5 stars
$2.68
+5.5%
$23.80
+788.1%
-66.0%$55.88M$1M-0.42190
CRGX
CARGO Therapeutics
2.3266 of 5 stars
$4.12
-1.7%
$15.00
+264.1%
-71.9%$193.20MN/A-0.89116News Coverage
Analyst Forecast
CYBN
Cybin
2.9239 of 5 stars
$8.39
+2.9%
$86.00
+925.0%
N/A$193.17MN/A-1.9250Analyst Forecast
EDIT
Editas Medicine
4.0586 of 5 stars
$2.20
-3.5%
$4.70
+113.6%
-37.3%$190.87M$32.31M-0.72230
EPRX
Eupraxia Pharmaceuticals
2.2141 of 5 stars
$5.76
+8.7%
$11.00
+91.0%
+106.0%$190.57MN/A-7.5829Positive News
Gap Up
High Trading Volume
ENGN
enGene
2.7897 of 5 stars
$3.64
-0.5%
$23.29
+539.7%
-57.5%$187.04MN/A-2.2131Trending News
TLSA
Tiziana Life Sciences
0.8186 of 5 stars
$1.58
-1.3%
N/A+86.2%$186.96MN/A0.008News Coverage
CTMX
CytomX Therapeutics
3.834 of 5 stars
$2.27
+0.9%
$5.33
+134.9%
+84.4%$181.40M$138.10M4.73170News Coverage
OGI
Organigram Global
0.9804 of 5 stars
$1.35
flat
N/A-8.3%$180.82M$117.47M13.50860News Coverage
GNFT
GENFIT
1.511 of 5 stars
$3.73
+3.2%
$13.00
+249.0%
-12.2%$180.49M$67.00M0.00120News Coverage
Gap Up
FDMT
4D Molecular Therapeutics
2.1288 of 5 stars
$3.71
-3.4%
$29.56
+696.6%
-80.5%$177.89M$40K-1.17120

Related Companies and Tools


This page (NASDAQ:ADVM) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners